Belgian Biotech Company Iteos Estimates Phase-Out Costs at Least $30 Million

11:01 Belgian Iteos Therapeutics, which is closing down, estimates the costs for severance payments at around 23 million dollars. This is according to a report to the American stock market watchdog SEC.